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Abstract: The major histocompatibility complex (MHC) is
one of the most extensively studied regions in the human
genome because of the association of variants at this
locus with autoimmune, infectious, and inflammatory
diseases. However, identification of causal variants within
the MHC for the majority of these diseases has remained
difficult due to the great variability and extensive linkage
disequilibrium (LD) that exists among alleles throughout
this locus, coupled with inadequate study design whereby
only a limited subset of about 20 from a total of
approximately 250 genes have been studied in small
cohorts of predominantly European origin. We have
performed a review and pooled analysis of the past
30 years of research on the role of the MHC in six
genetically complex disease traits – multiple sclerosis
(MS), type 1 diabetes (T1D), systemic lupus erythematosus
(SLE), ulcerative colitis (UC), Crohn’s disease (CD), and
rheumatoid arthritis (RA) – in order to consolidate and
evaluate the current literature regarding MHC genetics in
these common autoimmune and inflammatory diseases.
We corroborate established MHC disease associations and
identify predisposing variants that previously have not
been appreciated. Furthermore, we find a number of
interesting commonalities and differences across diseases
that implicate both general and disease-specific patho-
genetic mechanisms in autoimmunity.
Introduction
The major histocompatibility complex (MHC), located on the
short arm of Chromosome 6, is one of the most extensively studied
regions in the human genome because of the contribution of
multiple variants at this locus in autoimmune, infectious, and
inflammatory diseases and in transplantation. Historically, the
murine MHC locus, H2, was identified and subsequently named
for its role in histocompatibility almost 60 years ago by George
Snell [1]. Shortly afterward, Jean Dausset recognized the human
MHC, or human leukocyte antigen (HLA) region, so named
because Dausset originally demonstrated MHC antigens on the
surface of white blood cells [2]. Subsequently, Baruj Benacerraf
described the importance of these antigens in the immune
response [3]. The seminal work of Snell, Dausset, and Benacerraf
garnered them the 1980 Nobel Prize for Medicine.
The classical MHC encompasses approximately 3.6 megabase-
pairs (Mb) on 6p21.3 and is divided into three subregions: the
telomeric class I, class III, and the centromeric class II regions. The
concept of the extended MHC (xMHC), spanning about 7.6 Mb of
the genome, has been recently established by the finding that linkage
disequilibrium (LD) and MHC-related genes exist outside the
classically defined locus [4]. Of the 421 genes within the xMHC,
60% are expressed and approximately 22% have putative
immunoregulatory function. The five subregions of the xMHC
comprise the extended class I subregion, classical class I, classical
class III, classical class II, and the extended class II subregions [4].
The MHC was first associated with disease in 1967 when HLA-
B antigens were found at increased frequency in patients with
Hodgkin’s lymphoma [5]. Since then, variation within the MHC
has been found to be associated with almost every autoimmune
disease, as well as several infectious and inflammatory diseases.
However, because of the extensive LD that exists among alleles
throughout this locus, the causal MHC variant(s) have remained
elusive for the great majority of diseases.
Nonrandom association (or LD) in the inheritance of alleles at
multiple loci within the MHC was demonstrated as early as 1968
[6]. Upon determination of the physical size of the region, it
appeared that LD extended more than 2 Mb in some cases, but
not all. This differs from the LD pattern reported for other regions
in the genome where strong LD exists in segments of approxi-
mately 22 kilobases (kb) [7]. However, closer inspection reveals
that the ‘‘micro’’-structure of LD is similar for the MHC [8,9].
What appears to be different about a subset of MHC haplotypes is
that there is a higher amount of LD observed between segments of
strong LD. Such tight segment-to-segment LD can pose an
important obstacle in MHC research: if one identifies a disease
association with a variant in the region, it may not be possible to
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simply reflects LD with the true causal variation. Several studies of
the region to date have suffered from this caveat.
A further complication in the identification of disease-causing
variants at the MHC is the great variability exhibited by some of
the genes within the MHC (such as the classical class I genes, HLA-
A, -B, and -C and the classical class II genes, HLA-DRB1, -DQA1,
and -DQB1), which require typing strategies that are both labor-
and time-intensive; indeed HLA-B is the most polymorphic gene
known in the human genome.
The mechanisms underlying MHC association in autoimmune
disease are not clearly understood. One long-held view suggests a
breakdown in immunological tolerance to self-antigens through
aberrant class II presentation of self or foreign peptides to
autoreactive T lymphocytes. Thus, it seems likely that specific
MHC class II alleles determine the targeting of particular
autoantigens resulting in disease-specific associations.
For the reasons outlined above, most published studies of MHC
disease association to date have been restricted to small cohorts,
each testing a limited number of variants using a variety of typing
methodologies. This problem has resulted in a literature base that
can be complex and at times conflicting. We have therefore
examined the past 30 years of research regarding MHC genetics
in multiple autoimmune and inflammatory diseases using two
different approaches—(1) a review of published data and (2) a
pooled analysis of case–control association studies across the
region—in order to consolidate and evaluate the current literature
base. We chose to investigate six genetically complex disease traits:
multiple sclerosis (MS), type 1 diabetes (T1D), systemic lupus
erythematosus (SLE), ulcerative colitis (UC), Crohn’s disease (CD),
and rheumatoid arthritis (RA). By relying on combined data,
pooled analyses provide greater power for detecting disease-
associated variants, so may be helpful in corroborating or refuting
previous findings and establishing additional associations. Specif-
ically, we performed PubMed literature searches and identified
references from review sources to create a list of case–control
association studies across the region for each disease up to and
including September 2005 (see Table S1 for all disease-specific
studies included in the pooled analysis and Text S1 for further
search details). Only variants for which there were three
independent studies examining more than 50 cases each were
included in the final analysis. Phenotype and allele frequency data
were included but analyzed separately in this study. In total
approximately 390 studies were included across all diseases.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated for each serological, mixed lymphocyte reaction, or
molecular specificity (see Text S1). These data were collated
(Table S2) and used to create Figures 1 and 2. The extended LD
observed at the MHC does not allow differentiation between
allelic and haplotypic association in the current pooled analysis.
Thus, as it is vital to consider LD when interpreting association
results at the MHC, our figures display statistically significant
variants on the basis of ‘‘ancestral,’’ also known as ‘‘conserved
extended,’’ haplotypes [10–12].
The following text is subdivided by disease; for each we provide
a disease-specific review of the current literature on MHC genetics
and then detail the results of the pooled analysis (illustrated in
Figures 1 and 2) with respect to the variants found to confer risk to
disease (defined as a lower limit CI .1.0). A more comprehensive
account of MHC association for each disease can be found in
Datasets S1, S2, S3, S4, and S5. We also provide a brief
explanation of HLA nomenclature and typing methodologies (with
a mapping of serotypes to genotypes) because of the confusion that
often surrounds these topics (Text S2 and Table S3).
Multiple Sclerosis
MS (Online Mendelian Inheritance in Man [http://www.ncbi.
nlm.nih.gov/sites/entrez?db=omim] accession number [MIM]
126200) is a chronic inflammatory demyelinating disorder of the
central nervous system (reviewed in [13,14]). The only region of the
genome that has shown consistent evidence of linkage and
association with MS is the MHC (reviewed in[15]). The association
of the HLA-DR2 haplotype with MS was first noted in 1972 [16]
and remains one of the most reproduced findings in MHC genetics.
Due to strong LD across the associated haplotype, it remains
unclear whether the primary driver for the association of the HLA
locus to MS is the HLA-DQB1*0602 allele or the HLA-DRB1*1501
allele (reviewed in [15]). However, evidence is mounting that HLA-
DRB1*1501 and the closely related HLA-DRB1*1503 allele are
more strongly associated with MS in African-American [17] and
possibly European populations (PLD, unpublished data) when
compared to HLA-DQB1*0602. In addition, alleles within the
MHC class I region show suggestive evidence of association
independent of the DRB1*1501–DQB1*0602 haplotype, and
include HLA-A*0201 [18], HLA-A3 [15,18] and HLA-Cw05 [19]
as well as the HLA C1_3_2*354 microsatellite allele, although the
latter is in strong LD with HLA-DR3 [20].
There is support for allelic heterogeneity within the HLA-DRB1
gene, particularly in non-European MS populations [19,21]. The
best evidence for a second HLA-DRB1 risk allele in MS probably
lies with HLA-DRB1*03 (DR3) [19,22,23], although HLA-
DRB1*0103 and HLA-DR4 alleles may also increase disease risk
(reviewed in [13]) [19,24–26].
As expected, our pooled analysis highlights the preeminent role
of the extended haplotype defined by HLA-DRB1*1501 in MS
(Figure 1, top). Two other ancestral haplotypes containing HLA-
DR3 and HLA-DR4 also appear to play a role in MS susceptibility,
although the effect of these haplotypes on disease is more modest
than that of the HLA-DR2 haplotypes. In comparison to the HLA-
DRB1*1501 analysis, it is less clear whether the HLA-DRB1*0301
allele is primarily driving the association or whether one of the
alleles of tumor necrosis factor (TNF), for example, could be in
stronger LD with a risk allele. On the other hand, the HLA-DR4
haplotypes seem to display their strongest association with their
HLA-DRB1 alleles: four different HLA-DR4 alleles—0402, 0403,
0404, and 0405—display significant association in our analysis.
While the population risk of HLA-DR4 haplotypes on MS
susceptibility may be relatively small, those rare individuals
bearing these alleles may have a large increase in disease risk. In
MS, our pooled analysis highlights the class II gene HLA-DRB1 as
the primary candidate for MS susceptibility at the MHC, with a
number of different alleles contributing to disease risk (see Dataset
S1 for further information).
Type 1 Diabetes
T1D (MIM 222100) is a chronic autoimmune disease
characterized by T cell-mediated destruction of pancreatic islet
beta cells, resulting in irreversible insulin deficiency and long-term
dysfunction of several organs and tissues. There is no doubt that
the major genetic contribution to T1D susceptibility arises from
the MHC [27], accounting for approximately 50% of the total
genetic contribution to disease [28]. To date most evidence
supports a role for variation at HLA-DQ as the major disease-
predisposing locus [29,30].
The predominant role of DRB1*04–DQA1*0301–DQB1*0302
and DRB1*03–DQA1*0501–DQB1*0201 haplotypes in suscepti-
bility to T1D in European populations is borne out by several
studies [31]. Heterozygosity for both risk haplotypes confers the
PLoS Genetics | www.plosgenetics.org 2 April 2008 | Volume 4 | Issue 4 | e1000024greatest known genetic risk for T1D [31]. The formation of
specific trans DQ dimers by transcomplementation between HLA-
DQA1 and HLA-DQB1 alleles on homologous chromosomes
(DQA1*0301/DQB1*0201 and DQA1*0501/DQB1*0302) may be
responsible for the increase in heterozygote risk [27,32,33]. HLA-
DR4 (DRB1*0405–DQB1*0401) and HLA-DR9 (DRB1*0901–
DQB1*0303) have shown association with T1D in Japanese and
Korean populations [34]. The low frequency of the disease-
associated HLA-DR3 and HLA-DR4 haplotypes may contribute to
the reduced incidence of T1D in these non-European populations
[31].
The nature of the HLA-DR association in T1D remains unclear.
LD with HLA-DQ alleles may account for some of the association
[27], while certain DRB1 alleles may also modify the risk present at
the DQ locus. More recent studies, which require validation,
suggest a role for a non-HLA locus, telomeric of class I [35], as
well as polymorphism within HLA-DPB1 [36,37] in susceptibility
to T1D.
Overall, studies to date suggest that both HLA-DR and HLA-DQ
genes are important in determining disease risk, but the effects of
individual alleles may be modified by the haplotypes on which
they are carried [31]. There appears to be a hierarchy of risk
alleles from the strongly protective HLA-DQB1*0602 to the highly
predisposing HLA-DQB1*0302. Such a spectrum of risk is also
borne out by TDT (transmission disequilibrium test) analysis
showing that each HLA-DR/HLA-DQ haplotype has its own
individual disease risk, which may result from transcomplementa-
tion and other haplotypic effects.
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Figure 1. MHC susceptibility alleles identified by pooled analysis: Multiple sclerosis, type 1 diabetes, and systemic lupus
erythematosus. Susceptibility is defined as a lower CI greater than 1.0. Shown are odds ratios with 95% CIs for MS (upper graph), T1D (middle
graph), and SLE (lower graph). Beneath is a schematic representation of MHC class I, class III, and class II genes in genomic order but not to scale.
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DR4 and HLA-DR9-containing haplotypes in T1D (Figure 1,
middle). The HLA-DR9/HLA-DRB1*0901 associations we observe
arise from non-European cohorts only and concur with the
published literature. With regard to HLA-DPB1, we find
association with HLA-DPB1*0201, which maps to both disease-
associated and unrelated haplotypes. A number of other, mainly
class I alleles also show evidence for disease predisposition (see
Dataset S2) and warrant further investigation.
Systemic Lupus Erythematosus
SLE (MIM 152700), or lupus, is the prototypic, multisystem
autoimmune disease primarily affecting women of child-bearing
age. Recent genome-wide association scans and a meta-analysis of
linkage screens confirm the MHC as the greatest genetic risk factor
in lupus susceptibility ([38]; TJV, unpublished data). However, the
precise contribution attributable to the MHC with respect to
overall genetic risk remains to be determined.
The most consistent HLA associations with SLE reside with the
class II alleles, HLA-DR3 (DRB1*0301) and HLA-DR2
(DRB1*1501) and their respective haplotypes in predominantly
white populations [39]. Studies in nonwhite populations have
shown inconsistent results [40–44]. Inherited (and acquired)
deficiencies of the early classical complement components, C2,
C4A, and C4B, encoded within the class III region, are associated
with the development of lupus [45]. In particular, C4A and C4B
null alleles, which result in partial C4 deficiency, show association
with disease [46,47]. However, these alleles are in strong LD with
specific ancestral haplotypes, so to date it has not been possible to
establish whether C4 null alleles are causal in lupus. Recently the
development of autoimmunity in patients treated with TNF-alpha
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SLE [48–50]. However, the limited number of polymorphisms
genotyped and the strong LD between certain TNF alleles and the
B8-DR3 haplotype again restrict interpretation of these data.
In 2002, a family-based association study [51] identified three
microsatellite-inferred risk haplotypes in European lupus families:
DRB1*1501/DQB1*0602, DRB1*0301/DQB1*0201, and
DRB1*0801/DQB1*0402. Further analysis of ancestral recombi-
nants could only delimit the disease-associated region to 1 Mb of
the MHC, encompassing class II and class III.
Taking the above into account, it is not surprising that our
analysis demonstrates predominant association with variants
linked to DR3- and DR2-bearing ancestral haplotypes in SLE
(Figure 1, bottom). The observed DRB1*0401 signal principally
arises from Mexican Mestizo and Hispanic cohorts in whom this
allele is uncommon (frequency ,1%). This association has not
been well described and warrants further study. Two further class
II alleles, HLA-DQA1*0401 and HLA-DQB1*0402, reside on a
DR8 haplotype, which is infrequent in European populations
(frequency ,2%). Our pooled analysis highlights the importance
of polymorphism within HLA-DR3–containing haplotypes in lupus
susceptibility. The remaining association signals largely arise from
alleles of the class II genes HLA-DRB1, HLA-DQA1, and HLA-
DQB1 (see Dataset S3 for further information).
Inflammatory Bowel Diseases: Ulcerative Colitis
and Crohn’s Disease
CD and UC are related inflammatory diseases of the
gastrointestinal tract commonly known as inflammatory bowel
diseases (IBD, MIM 266600). Several independent genome-wide
scans in both CD and UC have shown evidence of linkage to the
MHC (IBD3 locus) [52–58]. It has been suggested that this region
may exert a greater effect in susceptibility to UC rather than CD
(with genetic contribution estimates of 60%–100% for UC and
10% for CD) [59].
The most consistent associations in UC are with the class II
alleles HLA-DRB1*1502 and HLA-DRB1*0103 [60–67]. HLA-
DRB1*1502 has shown association to UC in the Japanese
population, where it is highly prevalent (20%–25%)
[61,63,65,66], but also in European populations, where it is rare
(less than 1%) [68]. HLA-DRB1*0103 represents the most
reproducible association observed to date in UC [60,62,67,69–
72]; however, it has a low prevalence of less than 2% in Europeans.
In contrast to UC, four separate class II alleles show
reproducible association with CD: HLA-DRB1*07, HLA-
DRB1*0103, HLA-DRB1*04, and HLA-DRB3*0301 [67]. HLA-
DRB1*07 is the most consistently replicated association between
the MHC and CD [67,73–75], and more specifically with ileal
disease [73–75]. DRB1*0103, also associated with susceptibility to
UC [60,67,73–76], shows subphenotype specificity to colonic CD
[73–75]. HLA-DRB1*04 has shown a weak but reproducible
association [61,67,74,77,78] to CD, predominantly in patients of
Japanese origin. Finally, HLA-DRB3*0301 was also identified in
CD [67,73]; however; this locus has been evaluated in only a few
studies.
Our pooled analysis substantiates the association of UC to HLA-
DRB1*0103 and HLA-DRB1*1502 (Figure 2, top). We also detect
a weak predisposing effect of the microsatellite allele MICA5.1,
supporting previous non-replicated reports of association with
polymorphisms of the MHC class I-related gene, MICA, and UC
[66,79,80]. Other novel associations in UC are demonstrated for
HLA-DR5 (and its subspecificities HLA-DR11 and -DR12), HLA-
A19 and HLA-A24.
In CD, we confirm significant association signals arising from
alleles/haplotypes related to HLA-DRB1*0103, HLA-DRB1*04,
HLA-DR7, and HLA-DRB3*0301 (Figure 2, middle). We also
confirm previously reported association signals with HLA-B18 and
HLA-B21, and identify novel associations to HLA-DR6 (encom-
passing HLA-DRB1*1401), HLA-DR8 (including HLA-DRB1*0802
and *0803), and HLA-DR10. Finally, we substantiate previous
reports of association [81–85] of the TNF promoter polymorphism
TNF-857T with CD, and further show association with TNF-
1031C and TNF-863A (see Dataset S4 for further information).
Rheumatoid Arthritis
Rheumatoid arthritis (RA, MIM 180300) is a chronic systemic
disorder, the hallmark of which is an inflammatory polyarthritis. It
has been estimated that the MHC accounts for approximately
one-third of the overall genetic component of RA risk [86,87].
Much, but probably not all, of the risk attributable to the MHC
is associated with variation at HLA-DRB1. When the susceptible
HLA-DR subtypes were considered as a group, Gregersen et al.
noted ashared aminoacid sequence at positions70–74of the HLA-
DRB1 protein [88]. These alleles are now known collectively as
‘‘shared epitope’’ alleles because of the related sequence compo-
sition in the third hypervariable region: the susceptibility alleles
result in missense amino acid changes, where the shared
susceptibility amino acid motif is
70Q/R-K/R-R-A-A
74. The most
common (.5% population frequency) HLA-DRB1 shared epitope
susceptibility alleles include *0101, *0401, and *0404 in individuals
of European ancestry, and *0405 and *0901 in individuals of Asian
ancestry. The strength of genetic association to RA susceptibility
differs across the HLA-DRB1 alleles, there being at least two classes
of HLA-DRB1 risk alleles, high and moderate. In general, the
DRB1*0401 allele exhibits a high level of risk, with a relative risk
(RR) of approximately 3. The DRB1*0101, *0404, *1001, and
*0901 alleles exhibit a more moderate RR in the range of 1.5.
Several studies suggest that additional genes within the MHC
likely contribute to disease susceptibility once the effect of HLA-
DRB1 has been taken into consideration [89–93]. For example, an
extended haplotype that includes HLA-DRB1*03 alleles may be
associated with RA [89]. The associated haplotype spans
,500 kb, and contains MHC class III genes, including the TNF
locus implicated in other studies [92,94,95].
Genetic variation at the HLA-DRB1 gene is clearly associated
with RA. Our pooled analysis (Figure 2, bottom) also suggests the
existence of high and moderate risk alleles. The *0401 and *0405
alleles have ORs in the range of 3.5, with lower-limit 95% CIs
.3.0. The next class of HLA-DRB1 alleles have ORs in the 1.5–
2.0 range. These alleles include: *0101, *0404, *0901, and *1001;
additional DR4 alleles are also included in this group (Dw14_0404-
0408 alleles). Our analysis also supports the hypothesis that genetic
variation located a significant genomic distance away from the
HLA-DRB1 gene—and thus possibly not in LD with any of the
HLA-DRB1 risk alleles—also appears associated with RA risk. For
example, alleles near the TNF locus appear associated with RA
(see Dataset S5 for further information).
Conclusions
Our review and pooled analysis of MHC association in MS,
T1D, SLE, CD, UC, and RA corroborate established data and
identify predisposing variants that have not been previously
appreciated. Apart from IBD, this is the first time, to our
knowledge, that the published literature regarding MHC genetics
has been systematically analyzed in these diseases. Specifically, we
corroborate established data showing that HLA-DR2 and -DR3
PLoS Genetics | www.plosgenetics.org 5 April 2008 | Volume 4 | Issue 4 | e1000024containing haplotypes harbor lupus and MS susceptibility alleles in
European populations. We also demonstrate a putative predispos-
ing effect of HLA-DR4 haplotypes in these diseases: HLA-
DRB1*0401 (or a variant in LD with this allele) in non-European
lupus cohorts and several different HLA-DRB1*04 alleles in MS. In
RA we emphasize the high risk of both HLA-DRB1*0401 and
*0405 despite apparent molecular heterogeneity. We confirm an
established association with haplotypes containing DR3, DR4, and
DR9 in T1D. Furthermore we find hitherto unidentified class I
(MICA5.1 and HLA-A19) and class II (HLA-DR5, -6, -8, and -10)
association signals in IBD.
The pooled analysis highlights a number of commonalities as
well as differences across the six diseases (Figure 3). The most
frequently shared disease susceptibility alleles arise from HLA-DR4
haplotypes, which are observed in all cases except UC. HLA-DR3
haplotypes are clearly important in disease predisposition for SLE,
MS, and T1D, while DR9 haplotypes are seen in T1D and RA.
CD, UC, and RA share DR1 haplotypes, although the specific
DR1 alleles differ, as is the case in SLE, MS, and UC, where
different DR2 haplotypes are observed. The various TNF
polymorphisms that show disease predisposition in RA, CD,
MS, and SLE demonstrate an interesting paradox, as therapeutic
TNF-alpha blockade for CD and RA is associated with the
development of demyelination and antinuclear antibodies. The
susceptibility alleles/haplotypes identified in this review therefore
suggest both common and disease-specific pathogenetic mecha-
nisms in autoimmunity.
We emphasize that nearly all association studies of the MHC in
autoimmune and inflammatory disease to date have been limited
to a subset of ,20 genes and have been performed in small
cohorts of predominantly European origin. These genes include
the classical HLA loci (HLA-A, -B, -C, -DRB, -DQA, -DQB, -DPA,
and -DPB), TNF, LTA, LTB, the TAP genes, MICA, MICB, and the
complement loci (C2, C4, CFB). Moreover, most of these studies
individually investigated only a small proportion of this limited
subset of genes, thus impeding our ability to compare the strength
of association across studies for this limited number of loci. Given
that there are 421 genetic loci currently annotated to the xMHC,
approximately 252 (60%) of which are thought to be expressed, it
is necessary that a more comprehensive approach to the study of
the MHC in disease is undertaken in conjunction with conditional
analyses that address the issue of independent susceptibility loci
within the region. In order to differentiate the effects of tightly
linked loci, a dense map of variation is needed in large cohorts of
ethnically (thus haplotypically) diverse populations, so that rare,
distinguishing recombination events can be identified. Conditional
analyses can then be applied to separate allelic from haplotypic
association. Such statistical analyses are only now possible with
respect to the MHC. Indeed, the recently published MHC single
nucleotide polymorphism studies in MS [19], SLE [96] and T1D
Figure 3. Illustration of the principal shared and distinct MHC haplotype associations in six immune-mediated diseases
demonstrated by this pooled analysis. This Venn diagram illustrates the principal shared and distinct MHC haplotype associations in MS, T1D,
SLE, US, CD, and RA demonstrated by this pooled analysis. SLE is displayed at the centre of the figure, because it is a multisystem autoimmune
disease, while the surrounding diseases are predominantly, though not exclusively, organ-specific. The HLA-DR variants indicated in the figure
represent their respective extended haplotypes; TNF-alpha polymorphisms signify association at this gene alone.
doi:10.1371/journal.pgen.1000024.g003
PLoS Genetics | www.plosgenetics.org 6 April 2008 | Volume 4 | Issue 4 | e1000024[97] and the forthcoming IMAGEN (International Major
Histocompatibility Complex and Autoimmunity Genetics Net-
work) consortium data prove the utility of these experiments. Fine-
mapping and replication of the resulting independent association
signals in appropriately powered European and non-European
cohorts will present future challenges prior to moving forward with
functional studies. Undoubtedly, the next one to two years will be
witness to the identification of the causal variants within the MHC
in autoimmune disease.
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